Generic DYCLONINE HYDROCHLORIDE INN entry, drug patent expiry and freedom to operate

Sponsor	Phase
Peking Union Medical College Hospital	PHASE4
Changhai Hospital	Phase 4
Aaron Cumpston, PharmD	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	DYCLONE	dyclonine hydrochloride	SOLUTION;TOPICAL	009925-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Septodont	DYCLOPRO	dyclonine hydrochloride	SOLUTION;TOPICAL	200480-002	Nov 20, 2018		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Septodont	DYCLOPRO	dyclonine hydrochloride	SOLUTION;TOPICAL	200480-001	Nov 20, 2018		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Astrazeneca	DYCLONE	dyclonine hydrochloride	SOLUTION;TOPICAL	009925-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 3, 2026

Dyclonine hydrochloride is a mature, low-cost over-the-counter local anesthetic used primarily in sore-throat lozenges and oral-care products. Its commercial value comes from branded and private-label consumer-health products rather than from exclusivity around the active ingredient. The U.S. market has limited growth potential, high substitution risk and strong seasonality. No standalone revenue figures for dyclonine hydrochloride products are publicly reported by major manufacturers.

What is the current market position of dyclonine hydrochloride?

Dyclonine hydrochloride is a topical anesthetic that temporarily reduces pain in the mouth and throat. Its principal commercial form is the medicated lozenge, including products sold under the Sucrets brand. A commonly marketed strength is 2 mg of dyclonine hydrochloride per lozenge.[1]

The product occupies a narrow segment of the U.S. cough, cold and throat-care market. It competes with:

Benzocaine lozenges and sprays
Phenol throat sprays
Menthol lozenges
Pectin-based throat drops
Prescription-strength oral anesthetics
Combination cold and flu products

Dyclonine is differentiated from menthol and pectin by its local-anesthetic mechanism. Its main commercial disadvantage is that consumers can obtain similar symptomatic relief from a wide range of lower-cost products.

Dyclonine hydrochloride product profile

Attribute	Commercial position
Active ingredient	Dyclonine hydrochloride
Drug class	Topical local anesthetic
Main dosage form	Oral lozenge
Typical marketed strength	2 mg per lozenge
Primary indication	Temporary relief of minor sore-throat and oral pain
Main U.S. brand association	Sucrets
Prescription status	Primarily OTC
Biologic risk	None
Generic substitution risk	High
Revenue disclosure	No standalone public reporting

Dyclonine products are generally purchased for short-duration symptomatic treatment. That limits repeat use per consumer but supports recurring seasonal demand during fall and winter respiratory-illness periods.

How large is the dyclonine hydrochloride market?

A reliable global market size for dyclonine hydrochloride alone is not publicly available. Manufacturers generally report revenue by broader categories such as over-the-counter healthcare, cough and cold, or oral care. The active ingredient is a small subcategory within those markets.

The commercially relevant market is therefore best assessed through product economics rather than through an ingredient-specific market forecast.

Market characteristics

Market factor	Effect on dyclonine hydrochloride
Category size	Small relative to the overall OTC cough-and-cold market
Growth rate	Mature, low-growth category
Demand pattern	Seasonal and illness-driven
Pricing power	Limited
Retail dependence	High
Brand loyalty	Moderate to low
Private-label pressure	High
Switching cost	Minimal
Regulatory barrier	Low to moderate
Manufacturing complexity	Low

The category benefits from broad consumer awareness of throat-pain products and from the continued use of lozenges as an accessible self-care treatment. Volume is constrained by competition from inexpensive alternatives and by the fact that consumers often buy multi-symptom products instead of stand-alone anesthetic lozenges.

What is driving demand for dyclonine hydrochloride?

Demand is influenced by respiratory illness incidence, retail availability, brand promotion and product format.

Seasonal respiratory demand

Dyclonine sales are likely to be strongest during the fourth and first calendar quarters, when sore throat, influenza, respiratory syncytial virus and common-cold symptoms are more prevalent. Demand can also increase during severe respiratory-virus seasons, although higher illness rates do not translate directly into equivalent revenue growth because consumers may shift toward combination products.

Retail and channel dynamics

The product is sold through mass retailers, drugstores, grocery chains, e-commerce platforms and independent pharmacies. Shelf placement is important because the category is highly substitutable. Retailers can replace branded dyclonine products with:

Store-brand throat lozenges
Benzocaine products
Phenol sprays
Menthol drops
Combination cold remedies

E-commerce has increased assortment visibility but also makes price comparison easier. That tends to pressure branded products unless the brand has strong recognition or differentiated packaging.

Consumer behavior

Dyclonine hydrochloride is an episodic-use product. Consumers generally purchase it when symptoms appear rather than as part of a planned recurring regimen. This creates:

High dependence on distribution
Low switching costs
Limited patient retention
Heavy sensitivity to promotions
Low opportunity for premium pricing

What is the FDA regulatory status of dyclonine hydrochloride?

Dyclonine hydrochloride is regulated primarily as an OTC oral-healthcare active ingredient in the United States. The FDA’s OTC monograph framework includes topical oral-healthcare products intended to provide temporary relief of minor mouth and throat irritation.[2]

The regulatory position differs from that of a new prescription drug:

Products can be marketed under applicable OTC monograph conditions without an individual new-drug approval.
Manufacturers must comply with permitted active ingredients, concentrations, labeling and dosage directions.
Products outside the monograph conditions may require an FDA application or another valid regulatory pathway.
FDA oversight still applies to manufacturing, labeling, adverse-event reporting and product quality.

The FDA’s CARES Act OTC monograph system replaced the former monograph rulemaking structure with administrative orders and a more formal framework for OTC monograph products.[3]

FDA regulatory implications for manufacturers

For a dyclonine product, regulatory risk is more likely to arise from:

Labeling deviations
Manufacturing deficiencies
Drug-listing or establishment issues
Product-quality failures
Packaging and child-safety requirements
Inadequate substantiation of claims

The regulatory pathway is generally less burdensome than a prescription-drug approval but remains material for companies that manufacture or import large OTC volumes.

What patents protect dyclonine hydrochloride products?

The active ingredient is a mature compound, and the commercial product class does not appear to depend on a current composition-of-matter patent. The principal U.S. competitive barriers are commercial and operational rather than patent-based.

Potentially relevant intellectual-property categories include:

Formulation patents
Flavor and palatability technology
Controlled-release lozenge systems
Packaging and dispensing designs
Combination-product formulations
Manufacturing processes
Trademarks, especially brand names and trade dress

Orange Book status

Dyclonine hydrochloride OTC products generally do not have the same Orange Book structure as approved prescription products. The Orange Book is principally used for FDA-approved prescription and certain over-the-counter products approved through applications.[4]

As a result:

A conventional Orange Book patent listing is not the primary exclusivity mechanism.
Paragraph IV litigation is unlikely to be the standard route for challenging a monograph-compliant dyclonine lozenge.
Generic-style competition can arise without a formal patent certification dispute.
Trademark and unfair-competition claims may be more commercially relevant than drug-patent litigation.

No meaningful biosimilar risk exists because dyclonine hydrochloride is a small-molecule chemical ingredient, not a biologic.

When does dyclonine hydrochloride lose exclusivity?

Dyclonine hydrochloride already operates in a largely off-patent, mature market. There is no widely recognized upcoming loss-of-exclusivity event comparable to the expiration of a major prescription-drug patent.

The relevant exclusivity position is:

Exclusivity type	Current relevance
Composition-of-matter patent	Not a meaningful current barrier
Prescription exclusivity	Not applicable to the principal OTC market
New chemical entity exclusivity	Expired or irrelevant to current commercial products
OTC monograph protection	Regulatory compliance framework, not brand exclusivity
Trademark protection	Relevant for branded products
Formulation IP	Potentially relevant but product-specific
Retail placement	Commercial, not legal, exclusivity

A company entering the market would normally focus on regulatory compliance, supply reliability, packaging, brand positioning and retailer access rather than on designing around a blocking active-ingredient patent.

How strong is the dyclonine hydrochloride patent estate?

The patent estate is weak as a barrier to commodity competition but may be stronger around selected delivery systems or branded products.

Patent strength by category

Patent or IP category	Estimated strategic value
Active-ingredient patent	Low
Basic lozenge composition	Low to moderate
Combination product	Moderate if claims are narrow and enforceable
Controlled-release delivery	Moderate
Flavor-masking technology	Moderate
Manufacturing process	Low to moderate
Trademark and trade dress	Moderate to high for established brands
Regulatory data exclusivity	Low
Supply-chain qualification	Moderate

The strongest defensible assets are likely to be trademarks, retail relationships and proprietary product design. A generic manufacturer can generally compete by using the same active ingredient in a compliant product while avoiding protected branding and any enforceable formulation claims.

Which companies compete with dyclonine hydrochloride products?

The competitive landscape is fragmented. Sucrets is the most recognizable U.S. brand associated with dyclonine hydrochloride. Prestige Consumer Healthcare reports Sucrets within its broader OTC portfolio, but it does not separately disclose Sucrets or dyclonine revenue in its public financial statements.[5]

Competition comes from both branded and store-brand products.

Competitive set

Competitor category	Representative products or brands	Competitive effect
Dyclonine lozenges	Sucrets and private-label equivalents	Direct competition
Benzocaine lozenges	Cepacol and generic products	Strong therapeutic substitution
Phenol products	Chloraseptic and store brands	Strong substitution, especially sprays
Menthol lozenges	Halls and private labels	Lower-cost alternative
Pectin drops	Various store and branded products	Non-anesthetic substitution
Multi-symptom products	Cold and flu brands	Captures broader consumer need

The main strategic question is not whether dyclonine works as a local anesthetic. It is whether the product earns enough shelf space and consumer attention against cheaper and more heavily advertised substitutes.

What is the financial trajectory for dyclonine hydrochloride?

The financial trajectory is best characterized as stable-to-declining for mature branded products, with limited upside from category expansion. No public company separately reports dyclonine hydrochloride revenue, gross margin or unit volume.

Revenue profile

Dyclonine-related revenue is likely to have four characteristics:

Seasonal quarterly volatility.
Low absolute contribution relative to diversified OTC portfolios.
Gross-margin pressure from retailer and private-label competition.
Limited research-and-development spending because the ingredient and dosage forms are mature.

For a portfolio owner, the product can still generate cash flow because manufacturing and development costs are relatively low. The financial profile depends on maintaining distribution and avoiding costly manufacturing or quality events.

Financial sensitivity

Variable	Impact on dyclonine economics
Active pharmaceutical ingredient cost	Moderate, because unit prices are low
Packaging cost	Material due to small retail price points
Freight and warehousing	Material during seasonal inventory builds
Retailer discounts	High impact on branded margins
Promotional spending	Needed to defend shelf position
Product recalls	Potentially severe relative to product revenue
Private-label entry	Direct pressure on price and volume
E-commerce pricing	Increases price transparency
Respiratory season severity	Drives volume volatility

A modest increase in manufacturing cost can materially affect profitability because consumers have many substitutes and retailers can resist price increases. Portfolio owners therefore have an incentive to use common packaging, contract manufacturing and shared distribution infrastructure.

What manufacturing and supply-chain barriers exist?

Dyclonine hydrochloride products do not require the specialized manufacturing infrastructure associated with sterile injectables, biologics or complex inhaled medicines. The principal manufacturing requirements are conventional pharmaceutical controls for:

Active-ingredient identity and purity
Content uniformity
Lozenge hardness and dissolution
Flavor and stability
Microbiological quality
Packaging integrity
Accurate labeling

The active pharmaceutical ingredient can create supply risk if it is sourced from a limited number of qualified suppliers. Even when the ingredient is inexpensive, a supplier change may require qualification, quality documentation and production validation.

The more significant barrier is finished-product execution. A lozenge must balance anesthetic delivery, taste, texture, dissolution time and consumer acceptability. Poor palatability can reduce repeat purchases even when the active ingredient and labeled strength are equivalent.

What litigation and settlement risks affect dyclonine hydrochloride?

There is no prominent, recurring Paragraph IV litigation pattern associated with dyclonine hydrochloride OTC lozenges. The more relevant legal risks are:

Product-liability claims
Advertising and labeling disputes
Trademark infringement
Trade-dress claims
Consumer class actions involving ingredients or performance claims
Manufacturing-quality enforcement
Contract disputes with suppliers or retailers

Because the market is largely monograph-based, a generic entrant would not normally need to challenge a listed prescription patent through the standard Paragraph IV process. The absence of major patent litigation reduces entry costs but also limits the ability of a brand owner to delay competition.

How does dyclonine hydrochloride compare with competing throat anesthetics?

Factor	Dyclonine hydrochloride	Benzocaine	Phenol	Menthol
Primary effect	Local anesthesia	Local anesthesia	Local analgesic/anesthetic effect	Cooling and soothing
Common format	Lozenges	Lozenges, gels, sprays	Sprays and lozenges	Lozenges
Brand competition	Moderate	High	High	Very high
Differentiation	Moderate	Moderate	Moderate	Low
Consumer familiarity	Lower than menthol	High	High	Very high
Substitution risk	High	High	High	Very high
Patent barrier	Low	Low for mature products	Low	Low

Dyclonine can command a defensible niche when marketed as a stronger or more targeted throat-numbing product. That positioning is vulnerable to competing anesthetic products with greater brand recognition and broader distribution.

What generic launch scenarios exist for dyclonine hydrochloride?

Three commercial launch scenarios are most relevant.

Private-label launch

A retailer or contract manufacturer launches a store-brand dyclonine lozenge. This is the highest-probability competitive event because it requires limited consumer education and can use existing OTC distribution.

Branded line extension

An established cough-and-cold company adds dyclonine to an existing lozenge portfolio. The entrant benefits from shared sales infrastructure but must justify shelf space against the incumbent brand.

Combination product

A manufacturer combines dyclonine with another throat-care active ingredient or positions it in a multi-symptom product. This may create a more differentiated proposition but increases formulation, labeling and quality-control complexity.

The likely result of any successful entry is price pressure rather than rapid category expansion.

What geographic markets are commercially relevant?

The United States is the most important identifiable market because of the established OTC monograph framework and recognized branded products. Other markets may regulate dyclonine under different national rules, and product availability is less consistent.

Geographic expansion faces several constraints:

Different OTC active-ingredient rules
Country-specific labeling
Local monograph or approval requirements
Distinct brand and trademark ownership
Varying consumer preferences for lozenges and sprays
Different pharmacy and grocery distribution models

A company pursuing international growth would likely obtain more value from a broader throat-care platform than from dyclonine hydrochloride as a stand-alone ingredient.

Key Takeaways

Dyclonine hydrochloride is a mature OTC local anesthetic with limited standalone market visibility.
The main commercial form is the 2 mg lozenge, including Sucrets products.
No major current composition-of-matter patent or prescription exclusivity event drives the market.
Orange Book and Paragraph IV mechanisms are generally less relevant than they are for approved prescription drugs.
Private-label and benzocaine, phenol and menthol alternatives create high substitution risk.
Public companies do not separately disclose dyclonine revenue, margins or volumes.
The financial profile is likely stable-to-declining for branded products, with seasonal volume and persistent pricing pressure.
Supply reliability, retail access, trademark strength and product quality are more important than patent protection.
Biosimilar competition is irrelevant because dyclonine hydrochloride is a small-molecule drug.
The strongest commercial opportunity is as part of a broader OTC throat-care portfolio, not as a stand-alone growth asset.

FAQs

Is dyclonine hydrochloride available by prescription?

Dyclonine hydrochloride is principally marketed in OTC oral-care and throat products. Prescription use is not the primary commercial market.

Does dyclonine hydrochloride have a generic version?

Yes. The active ingredient is mature, and products can compete through compliant OTC formulations, private-label products and store brands.

Is Sucrets still a dyclonine hydrochloride product?

Sucrets products have historically included dyclonine hydrochloride as the active anesthetic ingredient. Product labeling should be checked because formulations can vary by product and market.[1]

Can a company launch a dyclonine lozenge without challenging a patent?

A company may be able to launch a compliant OTC product without a traditional Paragraph IV patent challenge, provided it avoids applicable formulation, trademark and trade-dress rights and satisfies FDA requirements.

What is the main investment risk for a dyclonine hydrochloride product?

The principal risk is commercial erosion from private-label products and therapeutic substitutes, not loss of a major patent. Retailer access, pricing and manufacturing quality determine financial performance.

References

DailyMed. (n.d.). Sucrets sore throat lozenge: Dyclonine hydrochloride 2 mg labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.). OTC monograph M003: Oral healthcare drug products for over-the-counter human use. https://www.accessdata.fda.gov/
U.S. Food and Drug Administration. (2020). Over-the-counter monograph drug products: Regulatory implementation of the CARES Act. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
Prestige Consumer Healthcare, Inc. (2024). Annual report for the fiscal year ended March 31, 2024. U.S. Securities and Exchange Commission. https://www.sec.gov/ixviewer/ +

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	5
What excipients (inactive ingredients) are in dyclonine hydrochloride?	dyclonine hydrochloride excipients list
DailyMed Link:	dyclonine hydrochloride at DailyMed

Summary for dyclonine hydrochloride

Recent Clinical Trials for dyclonine hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for dyclonine hydrochloride